Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. demonstrates a solid financial outlook, highlighted by its robust performance in the U.S. spine market, which outpaced overall market growth and contributed to a significant 10% revenue increase in the fourth quarter. The company benefits from a strong free cash flow trajectory, boasting an impressive 8% free cash flow yield while trading below historical valuation levels, indicating potential for upside. Additionally, the enabling technology segment has achieved its highest revenue to date, showcasing effective operational execution and enhanced growth prospects for the future.

Bears say

The financial outlook for Globus Medical Inc. presents several downside risks that contribute to a negative perspective on its stock. Key concerns include potential disruptions from the NUVA and NVRO mergers, alongside a deceleration in growth within the spine end market due to possible changes in reimbursement and pricing pressures. Additionally, the competitive landscape may intensify with new entrants gaining focus in the spine market, while underperforming product launches and slower growth in new musculoskeletal areas could further impact the company’s revenue trajectory and operating margins.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.